TABLE 8

ANTI-HA ANTIBODIES IN SERA OF MICE IMMUNIZED WITH HA ENTRAPPED IN LIPOSOMES

	DOSE/0.5 ml/INOCULUM		4 week		6 week		8 week		12 week	
HA FORMULATION	PROTEIN (ug),	LIPID (mg)	EIA	HAI	EIA	HAI	EIA	HAI	EIA	HAI
Non-Entrapped	5.0	—	26	29	516	557	301	368	198	320
	0.5	—	3	9	205	243	126	211	57	106
MLV, CHST, H	5.0	13.6	891	761	7062	7241	2170	3044	1581	1318
	0.5	1.4	52	33	2655	2941	1018	1237	557	640
MLV, CHST, L	5.0	1.9	147	92	3886	5553	3055	1810	1166	1191
	—	—	—	—	—	—	—	—	—	—
SPLV, DMPC/C, H	5.0	9.7	123	80	2204	1940	1548	1470	776	640
	0.5	1.0	22	23	387	399	233	243	136	121
SPLV, DMPC/C, L	5.0	2.9	101	89	1766	1810	1042	1613	767	905
	—	—	—	—	—	—	—	—	—	—

A/Liposomes (MLV, SPLV) were prepared with either 500 mg (H) or 50 mg (L) of lipid (CHST or DMPC/C, 70:30 mole percent)
B/Geometric mean titer (n-51) determined by enzyme-linked immuno assay (EIA) and hemagglutination inhibition (HAI)

We claim:

1. A method of potentiating an immune response in an animal which comprises administering to the animal a dosage form comprising:

(a) a liposome which comprises:

(i) a lipid consisting essentially of an organic acid derivative of a sterol; and,

(ii) an antigenic peptide; and,

(b) a pharmaceutically acceptable carrier,

wherein said organic acid is selected from the group consisting of a carboxylic, dicarboxylic, polycarboxylic, hydroxy, amino and polyamino acid attached to said sterol at a hydroxyl group by an ether or ester linkage, and wherein the liposome is present in the dosage form in an immunization dose.

2. The method of claim **1**, wherein the animal is a human.

3. The method of claim **1**, wherein the liposome is a multilamellar liposome.

4. The method of claim **1**, wherein the liposome has a size of about 1 micron.

5. The method of claim **1**, wherein the sterol is cholesterol.

6. The method of claim **1**, wherein the organic acid is a dicarboxylic acid having up to seven carbon atoms.

7. The method of claim **6**, wherein the acid is succinic acid.

8. The method of claim **1**, wherein the organic acid is citric acid.

9. The dosage form of claim **1**, wherein the sterol comprises a salt form of the organic acid.

10. The dosage form of claim **9**, wherein the salt form is a tris(hydroxymethyl)aminomethane salt.

11. The method of claim **1**, wherein the antigenic peptide is a viral peptide.

12. The method of claim **1**, further comprising administering an immunomodulator to the animal.

13. The method of claim **12**, wherein the immunomodulator is a cytokine.

14. The method of claim **1**, wherein the sterol is cholesterol hemisuccinate.

15. The method of claim **14**, wherein the salt form is the tris salt of cholesterol hemisuccinate.

16. The method of claim **14**, wherein the immunogen is a viral peptide.

* * * * *